Literature DB >> 12559369

Enhancement of antinociception by co-administration of an opioid drug (morphine) and a preferential cyclooxygenase-2 inhibitor (rofecoxib) in rats.

Myrna Déciga-Campos1, Uriah Guevara López, Maria Irene Díaz Reval, Francisco J López-Muñoz.   

Abstract

Synergism has been used to obtain analgesia at doses at which side effects are minimal. In addition, it has been demonstrated that inhibition of cyclooxygenase-2 is responsible for the therapeutic effects of nonsteroidal anti-inflammatory drugs (NSAIDs). The aim of this study was to evaluate the antinociceptive interaction between the preferential COX-2 inhibitor, rofecoxib and morphine. Several combinations were evaluated using the pain-induced functional impairment model (PIFIR), a rat model of arthritic pain. Surface of synergistic interaction (SSI) analysis and an isobolographic method were used to detect the antinociceptive potency of the drugs, given either individually or in combination. The surface of synergistic interaction was calculated from the total antinociceptive effect produced by the combination after subtraction of the antinociceptive effect produced by each individual drug. Male rats received orally morphine alone (10, 17.8, 31.6, 56.2 and 100.0 mg/kg), rofecoxib alone (3.2, 5.6, 10, 31.6, 56.2 and 74.0 mg/kg) or 12 different combinations of morphine and rofecoxib. Three combinations exhibited potentiation of antinociceptive effects (10 mg/kg of morphine with either 5.6, 10 or 31.6 mg/kg of rofecoxib), whereas the other nine combinations showed additive antinociceptive effects. The combination of morphine, 56.2 mg/kg (p.o.), and rofecoxib, 31.6 mg/kg (p.o.), produced the maximum antinociceptive effect (P<0.05). This combination caused gastric injuries less severe than those observed with indomethacin, i.e. it reduced ulcers and erosion formation. The synergistic antinociceptive effects of rofecoxib and morphine are important and suggest that combinations with drugs may decrease the side effects associated with the use of nonselective NSAIDs. Furthermore, the present results suggest that combinations containing opioid drugs and selective COX-2 inhibitors may have clinical utility in pain therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559369     DOI: 10.1016/s0014-2999(02)02920-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Influence of inflammatory nociception on the anxiolytic-like effect of diazepam and buspirone in rats.

Authors:  A Fernández-Guasti; R Reyes; L Martínez-Mota; F J López-Muñoz
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

Review 2.  Sex differences in innate immunity and its impact on opioid pharmacology.

Authors:  Hillary H Doyle; Anne Z Murphy
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

Review 4.  Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.

Authors:  Xue-Qing Hu; Yang Sun; Eric Lau; Ming Zhao; Shi-Bing Su
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.